Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fighting HIV with antibodies

09.04.2015

30 years after HIV was discovered to be the cause of the acquired immune deficiency syndrome (AIDS), and despite intensive research, no vaccine or cure has yet been found. 

An international team of scientists, in collaboration with the German Center for Infection Research (DZIF) and the University Hospital of Cologne, has now tested a new generation of antibodies in humans for the first time. They have demonstrated that these broadly neutralising antibodies significantly reduce the number of human immunodeficiency viruses (HIV) in infected patients’ blood. The results have been published in the renowned journal Nature.


Fighting HIV with Antibodies

Zach Veilleux, Rockefeller University

Today, HIV infections can be well controlled with a combination of different antiviral drugs. However, the drugs can cause some severe side effects, are expensive and have to be taken over a lifetime. Additionally, resistance can develop, which challenges individual treatment. “This is why we still need new treatment options,” explains Cologne infectious diseases specialist Prof Gerd Fätkenheuer, who is researching new ways of treating and preventing AIDS at the German Center for Infection Research.

In the trial, published today in Nature, doctors from the University Hospital of Cologne together with researchers of Michel Nussenzweig’s Laboratory from Rockefeller University in New York (USA) investigated a new treatment approach. For the first time, the scientists conducted human trials with an antibody (3BNC117), which was developed previously in Nussenzweig laboratory.

The special thing about this antibody is its ability to neutralise a large number of different human immunodeficiency viruses effectively. In the trial, which was co-funded by the DZIF, the antibody showed good tolerability and favourable pharmacological properties.

Furthermore, patients undergoing treatment at the highest dose level (30 mg per kg of bodyweight) showed a significant drop in viral load. “With this, the antibody has a potency comparable to the drugs we are currently using for treatment,” Fätkenheuer explains. The treatment effects could be observed for up to 28 days after administration of the antibodies.

The trial consequently opens up a new field in HIV treatment. Co-First Author Prof Florian Klein, who will soon be changing from the Rockefeller University to the University Hospital of Cologne, sees particular potential in the mechanism of action of broadly neutralising antibodies: “Neutralising antibodies have a different mechanism of action and different pharmacological properties compared to the HIV drugs that have been used up to now.”

According to the scientists, “Neutralising antibodies could play an important role in HIV treatment and HIV prevention.” Plans for clinical trials investigating the efficacy of broadly neutralising antibodies with regard to curing HIV are currently underway.

Current publication
Caskey, M.*; Klein, F.*(*Co-First Authors); Lorenzi, J.C.C.; Seaman, M.S.; West, A.P., Jr, Buckley, N.; Kremer, G.; Nogueira, L.; Braunschweig, M.; Scheid, J.F.; Horwitz, J. A.; Shimeliovich, I.; Avraham-Shulman, S.B.; Witmer-Pack, M.; Platten, M., Lehmann, C.; Burke, L.A.; Hawthorne, T.; Gorelick, R.J.; Walker, B.D.; Keler, T.; Gulick, R.M., Fätkenheuer, G.; Schlesinger, S.J.; Nussenzweig, M.C.:
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Nature, online first released on April 08 (2015)
DOI: 10.1038/nature14411

Contact
Prof Gerd Fätkenheuer
E-mail: g.faetkenheuer@uni-koeln.de

Prof Florian Klein
T +12123278367 /Mobile +17182900235
E-mail: fklein@rockefeller.edu

DZIF Press Office
Karola Neubert and Janna Schmidt
T +49531-6181-1170/1154
E-mail: presse@dzif.de

Press Office University Hospital of Cologne
Christoph Wanko
T +49221-478-88757
E-mail: Christoph.wanko@uk-koeln.de

Karola Neubert | idw - Informationsdienst Wissenschaft
Further information:
http://www.uk-koeln.de/

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>